Asthma Clinical Trial
Official title:
Expansion of the COPD At-risk Module in 4 States BRFSS Telephone Health Surveys
This cross-sectional survey study is intended to describe the characteristics of adults in 4 US states with regards to respiratory symptoms and tobacco exposure, utilizing an existing state-administered, CDC overseen Behavioral Risk Factor Surveillance System telephone health survey. The primary goal of study is to describe the sociodemographics, health behaviors, and presence of chronic diseases in persons with or at risk of having chronic obstructive pulmonary disease.
Objectives: The primary objective of this study is to determine the prevalence and
health-related characteristics of adults who are at high risk for COPD, but have never been
diagnosed. The second objective of this study is to determine the frequency and type of
respiratory symptoms in the general adult population among 4 states. The third objective is
to describe respiratory symptoms in the adult population in relationship to other chronic
diseases such as COPD, asthma, obesity and others. The fourth objective is to engage other
states to add the Module into their BRFSS as early as 2017 to aid in efforts to decrease the
burden of COPD.
Procedures: The COPD At-risk Module will be incorporated into 4 state's 2015 BRFSS telephone
health survey (SC, TX, FL, and KY). The COPD At-Risk Module was derived from previously
published COPD case-finding and population screening questionnaires. The 4 questions
contained in the Module are: 1) How many years have you smoked tobacco products? (asked of
those that say they smoked > 100 cigarettes/lifetime, which is part of core survey), 2) In
the last 30 days, how often are you short of breath? 3) How often do you cough up mucus or
phlegm? and 4) In the last 12 months, to what extent would you say your physical activities
are limited by shortness of breath? One additional question, age in years, is already
contained in the BRFSS, and when combined with the other 4 questions, will allow estimation
of survey participant's risk of COPD. The COPD risk categories are: 1) diagnosed COPD
(self-report of provider diagnosis of COPD), 2) high risk for COPD (self-report of frequent
respiratory symptoms based on participant responses plus at least 10 years of tobacco
product use), and 3) low risk (neither diagnosed COPD or in high-risk group).
Each state's BRFSS group (state government epidemiology departments) will undertake the
BRFSS telephone survey beginning January 2015 as part its normal annual state-based health
surveillance. The core BRFSS survey has been developed by the CDC and minor changes in the
core survey may occur each year. Individual states often have additional state-specific
questions such as those requested by outside organizations or individuals, such as done with
this study. The study investigators have requested and received approval to add the "COPD
at-risk Module" that consists of 4 questions will be added to the 70-plus sociodemographic
and health characteristic questions already included in the BRFSS.
Per CDC guidelines, potential survey respondents may refuse to participate or answer any
question in the survey. Using a scripted BRFSS, trained interviewers will collect data using
an independent prob¬ability sample of households through landline and cellular telephones of
non-institutionalized persons. Based on past BRFSS surveys, the participant response rates
have declined from ~ 60% to ~ 50% due to inclusion of cell phones along with landlines
beginning in 2011. According to the CDC, the inclusion of cell phones and landline phones
better represents the general adult population, especially in younger adults. A detailed
description of the survey's design and random sampling procedures is available in the BRFSS
Policies, Procedures, and Protocol Document, 2013 . The BRFSS has been approved as exempt
research by the CDC's institutional review board.
Study Population It is projected that there will be ~ 45,000 non-institutionalized adults (>
18 years) who will complete the 2015 BRFSS telephone health survey among the 4 participating
states - KY, SC, TX, and FL. These 4 states represent a significant segment of the COPD
population in the US based upon prior COPD prevalence estimates and COPD-related
hospitalizations among Medicare recipients. Of note, Kentucky has the highest prevalence of
COPD in the US. For each state, cell phone and landline phones are randomly selected based
on pre-determined goals for geographics and socio-demographics per state and CDC procedures.
Hispanics can also participate in the telephone survey through interpreters. Only one adult
in each household that is contacted can complete the survey. Of all potential survey
respondents, about one-half will provide complete data for the telephone survey.
Data Collection and Confidentiality Collection of survey data from participants will start
January 2, 2015 and be completed by the end of 2015. Prior to states analyzing and releasing
survey data in 2016, the CDC will undertake an internal review of each state's survey data
by May 2016.
Data files from the states and CDC that are shared with outside investigators contain no
PHI. After states review and analyze their survey data, it is then available to be released
to the public upon request, this includes investigators of this study.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|